
Opinion|Videos|August 23, 2024
Clinical Data Supporting Pneumococcal Vaccination
Key opinion leaders examine the pivotal clinical data that supported the FDA approvals of PCV15, PCV20, and PCV21, while also explaining the differences between polysaccharide and conjugate pneumococcal vaccines in terms of their induced immune responses and the durability of protection they offer.
Advertisement
Episodes in this series

What is the key data that led to the FDA-approvals of PCV15, PCV20, and PCV21?
How do the polysaccharide and conjugate pneumococcal vaccines differ in terms of immune response and durability?
- Can you discuss the potential long-term benefits of using conjugate vaccines over polysaccharide vaccines in adult populations and vice versa?
Newsletter
Stay informed on drug updates, treatment guidelines, and pharmacy practice trends—subscribe to Pharmacy Times for weekly clinical insights.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Pharmacy Times
1
Examining the Safety Profiles of SG and Pembrolizumab in ASCENT-04
2
Navigating the New Standard of Care: Patient Needs and the Pharmacist’s Critical Role in Perioperative MIBC Treatment
3
FDA Accepts Furosemide Autoinjector sNDA for Treatment of Edema in Chronic Kidney Disease or Chronic Heart Failure
4
RSV Vaccination as a Public Health Priority: Protecting Communities Through Pharmacy Access
5


















































































































































































































